Cannabigerol and cannabichromene in Cannabis sativa L. by MARJETA ZAGOŽEN et al.
355
Acta Pharm. 71 (2021) 355–364 Mini-review 
https://doi.org/10.2478/acph-2021-0021
Cannabigerol and cannabichromene in Cannabis sativa L.
In addition to delta-9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD), other phytocannabinoids, such as can-
nabigerol (CBG) and cannabichromene (CBC), also have 
beneficial effects on human health. A high content of CBG 
is found in plants with the B0 genotype, whereas CBC is 
independent of the allelic chemotype locus B. In basic re-
search models such as mice or rats, CBG has demonstrated 
anticancer properties, particularly against breast cancer. 
CBG has shown anti-inflammatory effects on murine colitis 
and on inflammatory bowel disease as well as stimulatory 
effects on the feeding behaviors of mice. It has also exhibi-
ted inhibition of aldose reductase, which is known to cause 
an accumulation of sorbitol and increase glucose levels in 
the blood, which may lead to diabetes. Cannabinoid CBC 
has also shown anti-inflammatory effects and reduced hy-
permobility in the gut and has displayed potential in vitro 
effect on adult neural stem progenitor cells. CBC also exerts 
modest analgesic properties in rodents, as well as anti-fun-
gal, anti-bacterial, pro-apoptotic, and anti-proliferative ef-
fects in tumor cells.
Keywords: cannabinoids, chemotype, health effects, hemp, 
receptors
INTRODUCTION
Hemp (Cannabis sativa L.) is an important herbaceous species that has been used for 
textile fibers and rope, as a source of food, in medicine, and in agriculture for seeds, animal 
food, silage, fuel, and animal bedding (1). C. sativa originated in Central Asia. It contains 
unique phytochemicals that have many therapeutic effects in various diseases and disor-
ders (1), with more than 500 phytochemicals having been detected in C. sativa to date (2). 
The most abundant among these are cannabinoids, terpenoids, steroids, flavonoids, lig-
nans and alkaloids. The most important and well-known secondary metabolites are can-
nabinoids, terpenophenolic compounds unique to Cannabis (3). The most well-known can-
nabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), as well as 
cannabigerol (CBG) and cannabichromene (CBC). The highest proportion of cannabinoids 
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Cannabinoids have many beneficial effects on human health. THC is the psychoactive 
compound in C. sativa, whereas CBD, CBG, and CBC are non-psychoactive compounds (5). 
CBD has antinociceptive, anxiolytic, antipsychotic, antiinflammatory, and antioxidant ef-
fects (5). CBG and CBC are also claimed to have antibacterial effects, whereas THC stimu-
lates appetite, reduces pain and spasticity while also functioning as a bronchodilator, neu-
roprotective antioxidant, and anti-inflammatory agent (6). 
Different phenotypes of C. sativa are characterized by specific cannabinoid ratios; five 
major chemotypes have been described (7). In 1973, Small and Becksted (8) determined 
three chemotypes: (i) chemotype I (“drug” type), with a THC content over 0.3 % (usually 
higher than 0.5 %, however, it can also be over 20 %) and a CBD content lower than 0.5 %, 
(ii) chemotype II (intermediate type), with the CBD and THC ratio roughly equal and (iii) 
chemotype III (“fiber” type), with a higher CBD and THC content lower than 0.3 %. Later, 
in 1987, Fournier et al. (9) described two additional chemotypes: chemotype IV, with a 
prevalence of CBG (> 0.3 %) and CBD (< 0.5%) and chemotype V, with an undetectable 
content of cannabinoids. Cannabinoid content depends on many different factors, such as 
length of the day (10), UV light intensity (11), temperature (12), plant nutrition (13, 14), sex 
and the maturity of the plant (15). 
The aim of this article is to summarize the literature data from investigations of can-
nabigerol and cannabichromene. Many studies on the health effects of CBD and THC have 
been made thus far, while only a few investigations have been devoted to CBG and CBC. 
Little is known about these non-psychoactive compounds (except CBD); thus, researchers 
still have great potential for further investigation.
THE BIOSYNTHETIC PATHWAY OF CBG AND CBC
To date, 113 different cannabinoids have been discovered (2). In plants, they appear in 
low concentrations except in rare chemotypes with a high CBG content (> 0.3 %). CBC 
constitutes about 0.3 % in C. sativa, but some varieties may contain significantly higher 
values (5). CBC was isolated in 1966 by Gaoni and Mechoulam (16). Cannabichromenic acid 
(CBCA), a precursor of CBC, predominates in young C. sativa plants, and its content de-
creases with maturation (1).
The precursors of cannabinoids have two biosynthetic pathways: (i) the polyketide 
pathway leading to olivetolic acid (OLA) and (ii) the plastidal 2-C-methyl-d-erythritol- 
-4-phosphate (MEP) pathway leading to geranyl diphosphate (GPP) synthesis (17). CBGA 
(cannabigerolic acid) is formed from the alkylation of OLA with GPP (18). The main can-
nabinoids are biosynthesized in the form of carboxylic acids and can then be decarboxyl-
ated by drying and heating the harvested plants. CBG (CBGA) is the direct precursor of 
the primary cannabinoids such as THC(A), CBD(A) and CBC(A). There are also homolo-
gous compounds with propyl side-chains, which are biosynthesized from cannabigerova-
rin (CBGV); these include cannabivarichromene (CBCV), cannabidivarin (CBDV) and 
delta-9-tetrahydrocannabivarin (THCV) (4).
THE BIOLOGICAL ACTIVITIES OF CBG AND CBC
The cannabinoids CBG and CBC have different affinities for receptors in the human 
body. The most important cannabinoid receptors are CB1 and CB2 (19); they are part of the 
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human endocannabinoid system which regulates multiple processes in the human body. 
The endocannabinoid system is composed of neurotransmitters and metabolizing en-
zymes along with the receptors mentioned above (19). CB1 receptors are found in the cen-
tral nervous system, especially in the basal ganglia, the hippocampus, the cortex, and the 
cerebellum, whereas CB2 receptors are found in peripheral regions. The binding of can-
nabinoids to these receptors has different effects: the binding to the CB1 receptor has a 
psychotropic effect (20), whereas binding to the CB2 receptor will result in an antiinflam-
matory effect. Besides CB1 and CB2, TRP (transient receptor potential) receptors are 
known. Their main task is to serve as ionotropic cannabinoid receptors. The TRP sub-
families are TRPV (transient receptor potential vanilloid), TRPA (transient receptor poten-
tial ankyrin), and TRPM (transient receptor potential melastatin) (21).
CBG was isolated from cannabis in 1964 by Gaoni and Mechoulam (22). Although it 
has a relatively weak agonistic effect at CB1 and CB2 receptors and an antagonistic effect 
at TRPV8, it stimulates cation channels from the TRP group (TRPV1, TRPV2, TRPA1, 
TRPA3, TRPV4) and α2-adrenoceptor activity (23), which are important for pain sensation, 
heat sensitization and inflammation. CBG can also stimulate serotonin by binding to 
5-HT1A (5-hydroxytryptamine receptor subtype 1A) and CB1 receptors. CBG is also a rela-
tively potent agonist for TRPM8 receptors, which can be important in prostate cancer, 
bladder pain, and detrusor overactivity. It can also have an antagonistic impact on sero-
tonin 5-HT1A, which is related to feelings of well-being and happiness (23). In 1982, Eisohly 
et al. (24) found that CBG also has a mild antifungal effect. CBG is found in the African 
Helichrysum species as well as in C. sativa (25).
There are CBC-rich Cannabis strains, which are the result of extensive cross-breeding 
(26). CBC has also been detected in Rhododendron anthopogonoides. It can interact with and 
stimulate the CB2 receptor by inhibition of endocannabinoid inactivation, but it has no 
activity on CB1 receptors (27). It also interacts with the TRP cation channels TRPA1, TRPV1-
4, and TRPV8, which are involved in pain relief and inflammation (5). When binding with 
TRP1 receptors, CBC can stimulate an antinociceptive effect in the brain. TRP1 and CB2 
are also known to be involved in the control of intestinal motility. CBC also activates 
TRPM8 receptors (28).
INHERITANCE OF CHEMICAL PHENOTYPES
Cannabigerol (CBG)
In 1987, Fournier et al. (9) described the fourth chemotype in C. sativa; this chemotype 
(IV) has a CBG content higher than 0.3 % and a CBD content lower than 0.5 %. As men-
tioned above, CBG is a direct precursor of THC (29), CBD (30) and CBC (16) (Fig. 1). The 
presence of the BD allele in C. sativa leads to a higher CBD content, whereas the presence 
of the BT allele leads to a higher THC content. CBG probably accumulates when the plant 
has a mutated allele called B0 encoding for a defective synthase enzyme (31). Through se-
lective breeding of C. sativa chemotypes, pure CBD plants have the BD/BD genotype (che-
motype III), pure THC plants have the BT/BT genotype (chemotype I), and plants accumu-
lating the CBG cannabinoid are presumed to have the B0/B0 genotype (chemotype IV). 
With cross breeding of CBG- prevalent and CBD-predominant plants, all of the resulting 
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generations will be strongly CBD- predominant (BD/B0 genotype), whereas cross-breeding 
of CBG-prevalent and THC-predominant plants results in offspring that are strongly THC- 
-predominant (BT/B0 genotype) in the F1 generation. This occurs because of the interaction 
between the fully recessive B0 allele with BD or BT. If plants have heterozygous BD/BT geno-
types, they will have a mixed CBD/THC chemotype with ratios about 1:1 due to the similar 
conversion of CBG into CBD and THC. In 2005, Meijer and Hammond (32) have suggested 
that CBG can (in small amounts) convert to CBD, which suggests that the B0 allele is a 
mutated form of BD. Discoveries have been made that show that all CBG-predominant 
genotypes contain CBD in proportions of 10–15 %. THC-predominant plants (BT/BT or BT/
B0 genotype) crossed with CBG-predominant plants (B0/B0 genotype) can display differen-
tiation between BT/B0 and BT/BT genotypes in the F2 generation. This can happen because 
of the residual ability of the synthase that encodes the B0 allele. As mentioned above, B0 is 
fully recessive in interaction with the BD and BT alleles in heterozygous combination, and 
this is the reason for the differentiation of the BT/B0 and BT/BT genotypes.
Fig. 1. Two separate loci (A and B) and CBG(V) precursor for conversion into CBD(V) and THC(V) and 
their encoding alleles (29).
Table I. Binding between cannabinoids and receptors and their impact on human health
Cannabinoid Receptor Health effect
CBG
TRPV1, TRPV2, TRPA1, TRPA3, TRPV4 
and α2-adrenoceptor
Pain sensation, heat sensation, 
inflammation
Weak agonist CB1, CB2, 5HT1A Serotonin
TRPM8 Prostate cancer, bladder pain, detrusor overactivity
CBC
CB2 Inhibition of endocannabinoid inactivation
TRPA1 Antinociception
TRPV1-4, TRPV8 Pain regulation, inflammation
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Locus A encodes two different alleles: APr, which is the encoded propyl form of CBG, 
and APe, which is the encoded pentyl form of CBG (CBGV). CBG and CBGV are converted 
equally into the end-products THC(V) and CBD(V) encoded by locus B (31). With self-fer-
tilization in monoecious populations of CBG-prevalent plants, a mutated B0 allele can 
become fixed in a few plants by repeated and frequent inbreeding (31).
Cannabichromene (CBC)
As mentioned above, CBG is a direct precursor of CBC (Fig. 2) (16). CBC is predomi-
nant in the juvenile phase and decreases in maturity. A high proportion of CBC is present 
in both CBD- and THC-predominant chemotypes but only in the phase of emergence, 
decreasing with aging. CBC-predominant plants can have a proportion of CBC up to 90 % 
in the phase of first true leaves, but this rapidly decreases to 1–5 %, the plant’s final content 
of CBC, depending on the variety. Three possibilities of profile change exist for CBC syn-
thase as C. sativa plants move from the juvenile phase to maturity. The first possibility is 
that CBC synthase activity is high in sessile trichomes, the second possibility is that dif-
ferent cannabinoid kinetic parameters influence synthases, and the third possibility is that 
CBC synthase is expressed only in the prolonged juvenile phase in plants with an ordinary 
low proportion of CBC (33).
The B0/B0 genotype offers an opportunity for breeding plants with high levels of CBC 
due to the completely obstructed CBG-THC and CBG-CBD pathways. As such, the CBC 
Fig. 2. Different conversions of CBG(V) and alleles for CBD(V), THC(V) and CBC(V) (31).
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synthase is competing only against a weak CBD synthase. CBC synthase activity is a fixed 
trait in C. sativa plants, and it is not under the control of locus-B-like CBD- and THC-syn-
thase activity (33).
In 2009, De Meijer and Hammond (33) discovered that the proportion of CBC in C. 
sativa increases with a reduction of light intensity, whereas the proportion of CBD, THC 
and CBG decreases with a reduction of light intensity.
HEALTH EFFECTS OF CBG AND CBC
Almost all biological properties of cannabinoids involve interactions with the endo-
cannabinoid receptors in the human body. The endocannabinoid system plays a regula-
tory role in physiological processes including pain sensation, memory, appetite, mood, 
insulin content, inflammation, and fat and energy metabolism (27). It works as a large 
signaling system and is characterized by many endocannabinoid receptors, including CB1, 
CB2, anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Lipid mediators, called endo-
cannabinoidome, play a role in the endocannabinoid system in sharing enzymes and re-
ceptors with endocannabinoids and also have the ability to inactivate molecular targets 
and enzymes. Botanical drugs that contain cannabinoids stimulate endocannabinoid re-
ceptors and endocannabinoidome proteins (34).
As mentioned by Appendino et al. (35), preparations from C. sativa were extensively 
investigated in the 1950s as active topical antiseptic agents, but these studies were not 
entirely accurate. Later, in 2008, this group found that all major cannabinoids, including 
CBG and CBC, showed potent antimicrobial properties against multidrug-resistance 
(MDR) strains of Staphylococcus aureus, also to EMRSA-15 and EMRSA-16. Of all the canna-
binoids, CBD and CBG showed the greatest impact on the resistance of these two strains 
of MRSA and were used for further research. Due to the role of phenolic hydroxyl which 
shows antibacterial properties, both, acetylation and methylation of the hydroxyl groups, 
had a negative effect on the activity against EMRSA. The minimum inhibitory concentra-
tion was higher than 100 µg mL–1. The monophenols CBC and THC had also shown potent 
activity, whereas monomethylation of diphenols CBD and CBG had resulted in low anti-
bacterial activity. CBD, CBG, and THC that were carboxylated had stronger antibacterial 
effects, while compounds with methylation of the carboxylic group had lower antibacte-
rial potency. Low antibacterial properties were also displayed in compounds after the 
 esterification of phenethyl alcohol. Phenolic acids have stronger antibacterial properties 
than the other compounds. Thus C. sativa represents an important source of antibacterial 
agents against MRSA and other pathogenic bacteria (35).
Beak et al. (36) and Ligresti et al. (37) found CBG to have an important ability to reduce 
cell proliferation in tumoral cell lines in in vitro studies. It is very cytotoxic in high doses 
on carcinoma in mice and is also highly effective against breast cancer. CBG was demon-
strated to have antidepressant effects in research animal models of rodents (37). CBG also 
has antiinflammatory effects on murine colitis, and it is assumed to be beneficial for pa-
tients affected by inflammatory bowel disease as well (1). It reduced colon mass/colon 
length ratio, which is an indicator of the inflammatory response, and had preventive and 
curative therapeutic effects; 30 mg per kg bm CBG reduced the rate of colon damage. The 
possible antioxidant effect of CBG in intestinal mucosa by reducing oxidative stress has 
also been studied.
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In 2016, Brierley et al. (38) investigated the effects of CBG on the food intake and feed-
ing behavior of male Lister hooded rats. They discovered that tests conducted for two 
hours showed CBG to be an appetite stimulant at a dose of 120–140 mg kg–1 bm. This is the 
dose to increase appetite and food intake, but it is unrealistically high since it would mean 
almost 10 g of pure CBG for a 70-kg man. Previous research, done by Farrimond et al. (39) 
in 2012, showed that CBG at a dose of 0.176–17.60 mg kg–1 bm had no significant impact on 
the feeding patterns of rats in a 4–h feeding test. CBG-induced hyperphagia may be a re-
sult of its potency as an antagonist of the α2-adrenoceptor (38). Cannabinoids that act as 
CB1 receptor agonists showed limited clinical utility as appetite stimulants, however, 
there is a possibility that CBG induces hyperphagia. In contrast to studies done in the past, 
THC formulations resulted in the largest increase in food intake in the first hour of feed-
ing, followed by a decrease in the second hour (39). Further investigations are needed for 
the evaluation of CBG as a therapeutic appetite stimulant.
In 2018, Smeriglio et al. (40) studied the inhibitory effects of non-psychoactive CBD and 
CBG cannabinoids on aldose reductase activity. They found that C. sativa CBD- and CBG-
type extracts and their CBDA- and CBGA-rich fractions showed statistically significant 
inhibition of aldose reductase. Aldose reductase causes intercellular accumulation of sor-
bitol and increased glucose levels in the blood, which leads to diabetes. This study shows 
the ability of C. sativa to help prevent or treat diabetes and the complications related to this 
disease.
CBC is one of the non-psychoactive cannabinoids that shows antiinflammatory (5), 
analgesic and sedative (41) effects. It reduces hypermobility in the gut induced by croton 
oil (28). CBC in combination with THC has a greater antiinflammatory effect (5). It showed 
potential in vitro effects on adult neural stem progenitor cells (42), but the in vivo medical 
research needs to be done to account for various physiological and pathological variations.
In their review article, Izzo et al. (43) described a modest analgesic activity in rodents 
with CBC as well as pro-apoptotic and antiproliferative effects in tumor cell lines such as 
the human prostate carcinoma, human breast carcinoma, human gastric adenocarcinoma, 
human colorectal carcinoma and rat basophilic leukemia. CBC also had antifungal and 
antibacterial effects (44) and showed potent activity against Staphylococcus aureus strains, 
similar to the effects of CBG (18).
CONCLUSIONS
Besides THC and CBD, C. sativa has other phytocannabinoids such as CBG and CBC, 
which also have beneficial effects on human health. Little is known about these non-psy-
choactive cannabinoids. Research on the beneficial health effects of CBG and CBC has 
mostly been carried out on animals (rats and mice) and not yet in humans. Thus, studies 
on the effects of CBG and CBC in humans are needed in the future.
Abbreviations/acronyms/symbols. – AEA – anandaminde, 2-AG – 2-arachidonoylglycerol, CB (1/2) 
– cannabinoid receptor, CBC – cannabichromene, CBCA – cannabichromenic acid, CBCV – canan-
nabivarichromene, CBD – cannabidiol, CBDV – cannabidivarin, CBGA – cannabigerolic acid, CBG – 
cannabigerol, CBGV – cannabigerovarin, GPP – geranyl diphosphate, 5-HT1A – 5-hydroxytrypta-
mine receptor subtype 1A, MDR – multidrug-resistance, MEP – methyl-d-erythritol-4-phosphate, 
MRSA – methicillin-resistant Staphylococcus aureus, OLA – olivetolic acid, PJC – prolonged juvenile 
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chemotype, THC – delta-9-tetrahydrocannabinol, THCV – delta-9-tetrahydrocannabivarin, TRP – 
transient receptor potential, TRPA – transient receptor potential ankyrin, TRPM – transient receptor 
potential melastatin, TRPV – transient receptor potential vanilloid.
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